Odylia Therapeutics Inc
| Fiscal year | Revenue | Expenses | Net | Reserve mo. | Staff % |
|---|---|---|---|---|---|
| 2018 | 20,657,445 | 184,728 | 20,472,717 | 1329.9 | 58% |
| 2019 | 1,275,847 | 1,465,742 | −189,895 | 84.2 | 4% |
| 2020 | 60,528 | 460,910 | −400,382 | 257.7 | 75% |
| 2021 | 343,480 | 498,271 | −154,791 | 234.4 | 84% |
| 2022 | 1,098,401 | 866,473 | 231,928 | 137.5 | 70% |
| 2023 | 570,773 | 867,236 | −296,463 | 133.5 | 55% |
In its most recent public year (2023), this organization spent $296,463 more than it brought in. Its reserves stood at about 133.5 months of spending, down from 1329.9 in 2018. Staff pay was 55% of spending.
Reserve months = net assets ÷ average monthly spending; net assets count everything the organization owns beyond its debts — buildings and donor-restricted funds included, not just cash. Staff pay = salaries, wages, and officer compensation; it excludes benefits and payroll taxes. The IRS releases this data years after the fact — this organization's newest public year is 2023. Years refer to the calendar year in which the organization's fiscal year ended. Short-form filers do not publicly report donor-restricted balances or staffing costs. Source filings
Odylia Therapeutics Inc's IRS filings as a feed — one entry per filing year, through 2023. Add the address to any feed reader; in Slack, send /feed subscribe with it (pasting the link alone won't subscribe). How this feed works